Algiers, Algeria – Saidal Group, Algeria’s leading pharmaceutical company, has entered into a memorandum of understanding (MOU) with Bioexpress Therapeutics, a Swiss biotechnology firm. The agreement signifies a commitment to bolstering international cooperation in the pharmaceutical and biotechnology sectors.
According to a statement released by Saidal, the MOU establishes a strategic framework for collaboration, primarily focusing on training and competency development in biotechnology. This initiative is designed to pave the way for a gradual and structured transfer of technology.
The partnership aims to create a conducive environment for the local production of biotechnological products. This will strengthen national capabilities and support the pursuit of health sovereignty within Algeria.
Through this agreement, Saidal reaffirms its dedication to supporting innovation, developing national expertise, and integrating advanced technologies. The group also intends to expand its network of strategic partnerships with leading international players in the pharmaceutical and biopharmaceutical industries.
This collaboration marks a significant step for Saidal in its ongoing efforts to modernize Algeria’s pharmaceutical sector and enhance its capacity to produce cutting-edge treatments locally.
